Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours

Using a previously developed enzyme-linked immunosorbent assay (ELISA), the levels of the receptor for urokinase-type plasminogen activator (uPAR) were determined in cytosols and corresponding membrane pellets derived from 878 primary breast tumours. The levels of uPAR in the pellet extracts were more than 3-fold higher than those measured in the cytosols (P< 0.001). Moreover, the uPAR levels in the two types of extracts were weakly, though significantly, correlated with each other (rS= 0.20, P< 0.001). In Cox univariate analysis, high cytosolic levels of uPAR were significantly associated with reduced overall survival (OS) and relapse-free survival (RFS). The levels of uPAR in pellet extracts appeared not to be related with patient survival. In multivariate analysis, elevated levels of uPAR measured in cytosols and pellet extracts were found to be independent predictors of poor OS, not RFS. The prediction of poor prognosis on the basis of high uPAR levels emphasizes its important role in plasmin-mediated degradation of extracellular matrix proteins during cancer invasion and metastasis. © 2001 Cancer Research Campaign http://www.bjcancer.com

[1]  N. Brünner,et al.  The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. , 2000, Cancer research.

[2]  V. Bécette,et al.  Dissemination risk index based on plasminogen activator system components in primary breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  H. Nielsen,et al.  Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. , 1999, Journal of the National Cancer Institute.

[4]  J. Foekens,et al.  Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer , 1999, British Journal of Cancer.

[5]  J. Foekens,et al.  Clinical relevance of the urokinase plasminogen activator system in breast cancer , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[6]  J. Foekens,et al.  Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients , 1999, British Journal of Cancer.

[7]  N. Brünner,et al.  The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. , 1998, Cancer research.

[8]  H. Chapman,et al.  Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. , 1997, Current opinion in cell biology.

[9]  H. Nielsen,et al.  ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. , 1997, Clinical chemistry.

[10]  N. Brünner,et al.  ELISA for complexes between urokinase‐type plasminogen activator and its receptor in lung cancer tissue extracts , 1997, International journal of cancer.

[11]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[12]  H. Höfler,et al.  Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy , 1997, Thrombosis and Haemostasis.

[13]  N. Brünner,et al.  Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. , 1997, European journal of cancer.

[14]  K. Danø,et al.  Domain Interplay in the Urokinase Receptor , 1996, The Journal of Biological Chemistry.

[15]  Michael V. Doyle,et al.  Regulation of Integrin Function by the Urokinase Receptor , 1996, Science.

[16]  K. Preissner,et al.  The urokinase receptor is a major vitronectin-binding protein on endothelial cells. , 1996, Experimental cell research.

[17]  M. Duffy,et al.  Proteases as prognostic markers in cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  N. Brünner,et al.  Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  M. Duffy,et al.  Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer , 1995, International journal of cancer.

[20]  K. Danø,et al.  The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface. , 1995, Biological chemistry Hoppe-Seyler.

[21]  N. Brünner,et al.  The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion , 1995 .

[22]  S. Rosenberg,et al.  Identification of the urokinase receptor as an adhesion receptor for vitronectin. , 1994, The Journal of biological chemistry.

[23]  D. Waltz,et al.  Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. , 1994, The Journal of biological chemistry.

[24]  H. Nielsen,et al.  Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked immunosorbent assay. , 1994, Journal of immunological methods.

[25]  F. Blasi.  The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion , 1994 .

[26]  N. Brünner,et al.  Urokinase-type receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies , 1994 .

[27]  B. Nielsen,et al.  An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator , 1993, FEBS letters.

[28]  D. Rifkin,et al.  Biology and biochemistry of proteinases in tumor invasion. , 1993, Physiological reviews.

[29]  N. E. Hansen,et al.  A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria. , 1992, European journal of biochemistry.

[30]  F. Blasi,et al.  Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract , 1991, The Journal of cell biology.

[31]  K. Danø,et al.  Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. , 1991, The Journal of biological chemistry.

[32]  K. Danø,et al.  Plasminogen Activation by Receptor-Bound Urokinase , 1991, Seminars in thrombosis and hemostasis.

[33]  F. Blasi,et al.  Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. , 1991, The Journal of biological chemistry.

[34]  S. Stacey,et al.  Plasminogen activator inhibitors: hormonally regulated serpins , 1990, Molecular and Cellular Endocrinology.

[35]  J. Foekens,et al.  Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. , 1989, Cancer research.

[36]  K. Danø,et al.  Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.

[37]  Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute. , 1980, European Journal of Cancer.

[38]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[39]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .